The role of protein traffic in the progression of renal diseases

P Ruggenenti, G Remuzzi - Annual review of medicine, 2000 - annualreviews.org
P Ruggenenti, G Remuzzi
Annual review of medicine, 2000annualreviews.org
Progression to irreversible renal parenchymal damage and end-stage renal disease is the
final common pathway of chronic proteinuric nephropathies and is relatively independent of
the type of initial insult. In animals, a reduction in nephron mass exposes the remaining
nephrons to adaptive hemodynamic changes that are intended to sustain renal function but
may be detrimental in the long term. High glomerular capillary pressure impairs glomerular
permeability to proteins, which are then filtered in excessive quantities and reach the lumen …
Progression to irreversible renal parenchymal damage and end-stage renal disease is the final common pathway of chronic proteinuric nephropathies and is relatively independent of the type of initial insult. In animals, a reduction in nephron mass exposes the remaining nephrons to adaptive hemodynamic changes that are intended to sustain renal function but may be detrimental in the long term. High glomerular capillary pressure impairs glomerular permeability to proteins, which are then filtered in excessive quantities and reach the lumen of the proximal tubule. The secondary process of reabsorption of filtered proteins can contribute substantially to renal interstitial injury by activating intracellular events, including upregulation of vasoactive and inflammatory genes. The corresponding molecules formed in excessive amounts by the renal tubules cause an interstitial inflammatory reaction that normally precedes renal scarring and correlates with declining function. In several clinical studies, the increase in urinary protein excretion correlated with the tendency of the renal disease to progress more than it correlated with the underlying renal disease itself. Whenever urinary protein excretion is reduced, the decline in the glomerular filtration rate (GFR) slows or stops. Thus, to the extent that angiotensin-converting enzyme inhibitors lower the rate of urinary protein excretion, they effectively limit the progressive decline in GFR. If treatment is sufficiently prolonged, the GFR decline can be effectively halted or reversed, even in patients with remarkably severe disease, and remission is now achievable in some patients.
Annual Reviews